Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients

CONCLUSION: Icotinib neoadjuvant therapy for NSCLC is safe and feasible, and the reactivity of lung cancer patients to icotinib can be determined within 2 weeks of medication. People sensitive to preoperative selection of drugs can more accurately determine the sensitivity of tumors to drugs, thus providing evidence for postoperative adjuvant therapy.

Source: Indian Journal of Cancer - December 1, 2017 Category: Cancer & Oncology Authors: T Wang Y Liu B Zhou S Hao Z Wang N Liang J Liu S Wang Source Type: research